1. Scrip
  2. >>Business
  3. >>Deals

Alkermes Invests In Novel CNS Targets With Rodin Acquisition

 
• By Jessica Merrill

Rodin is developing HDAC CoREST complex inhibitors for neurological conditions, with a lead candidate having completed Phase I testing. Alkermes will pay $100m upfront.

Human brain is surrounded by a network of polygons on a dark blue background. Conceptual digital illustration - Illustration
Alkermes is expanding its early CNS pipeline

Alkermes PLC is building out its strategy to become a CNS drug developer with the acquisition of Rodin Therapeutics Inc. for $100m upfront. The company announced an agreement to buy privately-held Rodin on 18 November, gaining a platform for developing small molecule drugs for synaptopathies. In addition to the upfront, Alkermes could also pay future payments of $850m tied to certain clinical and regulatory milestones and certain sales thresholds.

Rodin is developing first-in-class, orally-available, brain-permeable therapeutics for neurodegenerative diseases like Alzheimer's, Huntington's and dementia that target specific histone deacetylase (HDAC) complexes

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

Will Other Major MASH Deals Follow GSK/Boston Pharma?

 
• By Joseph Haas

GSK’s $1.2bn payout for Boston Pharma’s efimosfermin is the first billion-dollar-plus MASH deal in nearly nine years, but several other advanced MASH programs could be positioned for takeout.

AbbVie Pays $335m Up Front To Partner With ADARx On siRNA Therapeutics

 
• By Mandy Jackson

ADARx CEO Zhen Li told Scrip the collaborators will advance novel siRNA medicines, but ADARx retains its clinical-stage and many preclinical programs and remains open to more deals.

Bluebird, Private Equity Firms Look To Sweeten Buyout Deal

 
• By Alaric DeArment

Shareholders are being offered a flat fee of $5 per share as an alternative to $3 plus a contingent value right, which could be a more attractive option if they want cash up front.

Novo Nordisk Looks To Septerna For Oral Obesity Options

 
• By Mary Jo Laffler

Deal Snapshot: The Danish drugmaker is partnering with GPCR drug discovery expert Septerna to develop multiple small molecules for cardiometabolic targets.

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.